Gilgamesh Pharmaceuticals is a pharmaceutical company that is developing psychedelic and related drugs as medicines.[2][3][4] It is a "discovery stage" company and is focused on developing new chemical entities.[1]
Its drug candidates include the ketamine-related NMDA receptor antagonist blixeprodil (GM-1020; (R)-4-fluorodeschloroketamine or (R)-4-FDCK), the dimethyltryptamine (DMT)-related serotonergic psychedelic bretisilocin (GM-2505; 5-fluoro-N-methyl-N-ethyltryptamine or 5F-MET), the noribogaine-related κ-opioid receptor agonist GM-3009, and the non-hallucinogenic psychoplastogen GM-5022.[2]